Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q1 FY22 Earnings Presentation
25 slides from Dishman Carbogen Amcis's earnings presentation, Aug 12, 2021
Slide 1: Cover letter to stock exchanges
dish man 12th August, 2021 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, "Exchange Plaza", C-1, Block G, Mumbai - 400 001. Bandra-Kurla Complex, Ban�ra (E), Mumbai - 400 051. Ref.: Scr
Slide 2: Quarter ended June 30th, 2021
Quarter ended June 30th, 2021 August 2021
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING Dedicated R&D Labs, including APIS in R&D - 950+ FACILITIES Globally H
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 20,586 20,436 4,087 19,120 5,519 3,660 17,137 16,948 4,976 4,534 4,453 2,994 26.8% 24.3% 2,538 26.3% 2,744 26.5% 14.3% FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
QUARTER HIGHLIGHTS
Slide 8: Q1 FY22 Result Highlights
Q1 FY22 RESULT HIGHLIGHTS NET REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 5,293 5,507 4,744 1,006 884 431 16.7% 18.3% 9.1% Q1FY21 Q4FY21 Q1FY22 Q1FY21 Q4FY21 Q1FY22 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS (₹ ) 8.4% 5.8% 5.5 461 4.9 306 872 776 2.7 -2.4% 430 -115 Q1FY21 Q4FY21
Slide 9: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q1 FY22 Q1 FY21 YoY % Q4 FY21 QoQ% FY21 Income from Operations (Net) 5507.3 4,744.1 16.1% 5,293.2 4.0% 19,120.3 COGS 1284.7 1,487.4 -13.6% 1,663.9 -22.8% 4,681.50 Employee Expenses 2390.3 2,140.2 11.7% 2,197.7 8.8% 8,729.1 Other Expenses 825.9 685.9 20.4
Slide 10: Segment Wise Revenue Analysis
SEGMENT WISE REVENUE ANALYSIS Revenues – Segment wise Breakup (₹ mn) Q1 FY22 Q1 FY21 YoY % Q4 FY21 QoQ% FY21 CRAMS (% of total) 70.0% 73.6% 73.1% 74.9% CRAMS - India 324.4 147.8 119.5% 226.5 43.2% 533.9 CRAMS - Switzerland, France & China 3,205.7 3,089.8 3.8% 3,425.4 -6.4% 12,804.0 CRAMS - UK 322.7
Slide 11: Segment Wise Revenue Break-up
SEGMENT WISE REVENUE BREAK-UP Total Operating Revenue – Q1 FY22 CRAMS – 70.0% Marketable Molecules – 30.0% 8.4% 4.2% 8.4% 2.4% 29.0% 71.0% 76.6% CRAMS - India CRAMS - Switzerland CRAMS - France CRAMS - China Carbogen Amcis BV Others CRAMS - UK 10
Slide 12: Segment-wise Margin Analysis
SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin* % Q1 FY22 Q1 FY21 Q4 FY21 FY21 CRAMS CRAMS- India - NA - - CRAMS – Switzerland, France & China 19.3% 16.2% 18.6% 19.0% CRAMS - UK 19.6% 15.3% 21.6% 19.5% Marketable Molecules Carbogen Amcis BV 29.5% 32.3% 26.0% 32.3% Others 5.5% 12.9% 19.1% 16.3% *includes
Slide 13: Q1 FY22 Result Highlights
Q1 FY22 RESULT HIGHLIGHTS Net Revenue at Rs 5,507 mn in Q1 FY22 up by 16.1% YoY CRAMS revenue increased by 10.4% YoY primarily due to: CRAMS India revenue increased by 119.5% due to re-commencing production for CRAMS customers from Bavla site. CRAMS UK revenue increased by 28.1% due to higher supply
Slide 14: Company Overview
COMPANY OVERVIEW
Slide 15: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 16: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 17: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 18: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 19: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES § Focus is on supporting the development process from bench to market § Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 20: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 21: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY21 FY21 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 20
Slide 22: Industry Overview
Dishman Carbogen Amcis INDUSTRY
Slide 23: Top 20 Therapy Areas (US$ bn) - 2025
2025 Expected Global Spending by Therapy Areas Oncology & Immunology expected to dominate sales and grow by 9-12% CAGR through 2025 5-Yr CAGR 2021-2025 Oncologics 273 9-12% Immunology 175 9-12% Top 20 Therapy Areas (US$ bn) - 2025 Antidiabetics 148 4-7% Neurology 143 3-6% Cardiovascular 74 1-4% Anti
Slide 24: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Specialty medicines will represent nearly half of global spending in 2025 and almost 60% of total spending in developed markets 59% 47% 45% 41% 37% 38% 35% 28% 29% 24% 21% 21% 17% 14% 9% 10% 2010 2015 2020 2025 Pharmerging Other Developed Global 10 Developed 23 Sourc
Slide 25: Thank you!
Dishman Dishman Carbogen Amcis Limited CARBOGEN AMCIS AG Dishman Corporate House Hauptstrasse 171 Ambli Bopal Road CH-4416 Bubendorf Ahmedabad 380 058 Switzerland www.dishmangroup.com www.carbogen-amcis.com Thank you! FOR FURTHER QUERIES Mr. Binay Sarda Mr. Harshil Dalal Christensen IR Group CFO P:
Dishman Carbogen Amcis — Q1 FY22 Earnings Presentation on 6ix